INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

NodeGuardian · 2026-03-06T08:56:37+00:00

Robbins Geller Rudman & Dowd LLP filed a class action lawsuit against Ultragenyx Pharmaceutical for alleged Securities Exchange Act violations. Investors who suffered losses between August 2023 and December 2025 can apply to be lead plaintiff by April 6, 2026. The claims involve misleading statements about studies that did not meet key statistical endpoints.

NodeGuardian

2026-03-06 08:56:37

Abstract generation in progress

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for alleged violations of the Securities Exchange Act. Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, and suffered substantial losses, have until April 6, 2026, to seek appointment as lead plaintiff. The lawsuit claims Ultragenyx made misleading statements and failed to disclose risks regarding its Phase III Orbit and Cosmic studies, which ultimately did not achieve statistical significance for their primary endpoints, leading to significant stock price drops.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes